FI3712264T3 - Kystationiini-beta-syntaasientsyymi homokystinurian hoitoon - Google Patents

Kystationiini-beta-syntaasientsyymi homokystinurian hoitoon Download PDF

Info

Publication number
FI3712264T3
FI3712264T3 FIEP20168207.7T FI20168207T FI3712264T3 FI 3712264 T3 FI3712264 T3 FI 3712264T3 FI 20168207 T FI20168207 T FI 20168207T FI 3712264 T3 FI3712264 T3 FI 3712264T3
Authority
FI
Finland
Prior art keywords
polypeptide
htcbs
amino acid
isolated
pharmaceutical composition
Prior art date
Application number
FIEP20168207.7T
Other languages
English (en)
Finnish (fi)
Inventor
Jan P Kraus
Tomas Majtan
Erez Bublil
Original Assignee
Univ Colorado Regents
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Colorado Regents filed Critical Univ Colorado Regents
Application granted granted Critical
Publication of FI3712264T3 publication Critical patent/FI3712264T3/fi

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51Lyases (4)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88Lyases (4.)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y402/00Carbon-oxygen lyases (4.2)
    • C12Y402/01Hydro-lyases (4.2.1)
    • C12Y402/01022Cystathionine beta-synthase (4.2.1.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
FIEP20168207.7T 2013-01-29 2014-01-29 Kystationiini-beta-syntaasientsyymi homokystinurian hoitoon FI3712264T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361758138P 2013-01-29 2013-01-29
US13/803,804 US9034318B2 (en) 2011-08-30 2013-03-14 Chemically modified cystathionine beta-synthase enzyme for treatment of homocystinuria

Publications (1)

Publication Number Publication Date
FI3712264T3 true FI3712264T3 (fi) 2024-05-07

Family

ID=51223166

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP20168207.7T FI3712264T3 (fi) 2013-01-29 2014-01-29 Kystationiini-beta-syntaasientsyymi homokystinurian hoitoon

Country Status (12)

Country Link
US (4) US9034318B2 (cg-RX-API-DMAC7.html)
EP (4) EP3282013B1 (cg-RX-API-DMAC7.html)
JP (4) JP6453243B2 (cg-RX-API-DMAC7.html)
CN (2) CN105452457A (cg-RX-API-DMAC7.html)
AU (3) AU2014212471B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015017775A2 (cg-RX-API-DMAC7.html)
DK (1) DK3712264T5 (cg-RX-API-DMAC7.html)
FI (1) FI3712264T3 (cg-RX-API-DMAC7.html)
HK (1) HK1213291A1 (cg-RX-API-DMAC7.html)
IL (1) IL239783B (cg-RX-API-DMAC7.html)
PT (1) PT3712264T (cg-RX-API-DMAC7.html)
WO (1) WO2014120770A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7485307B2 (en) 2002-06-17 2009-02-03 The Regents Of The University Of Colorado Human cystathionine β-synthase variants and methods of production thereof
US9034318B2 (en) * 2011-08-30 2015-05-19 The Regents Of The University Of Colorado, A Body Corporate Chemically modified cystathionine beta-synthase enzyme for treatment of homocystinuria
US9675678B2 (en) 2013-01-29 2017-06-13 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for treatment of homocystinuria
KR101947053B1 (ko) 2013-10-18 2019-02-12 도이체스 크렙스포르슝스첸트룸 전립선 특이적 막 항원(psma)의 표지된 억제제, 조영제로서의 이의 용도 및 전립선암 치료용 약제
DK3998067T3 (da) * 2015-11-09 2024-10-28 Univ Colorado Regents Sammensætninger og fremgangsmåder til behandling af homocystinuri
CA3059592A1 (en) * 2017-04-17 2018-10-25 The Regents Of The University Of Colorado, A Body Corporate Optimization of enzyme replacement therapy for treatment of homocystinuria
AU2018266879B2 (en) 2017-05-12 2024-09-05 Board Of Regents, The University Of Texas System Human-enzyme mediated depletion of homocysteine for treating patients with hyperhomocysteinemia and homocystinuria
US20190309271A1 (en) 2018-03-20 2019-10-10 Rubius Therapeutics, Inc. Therapeutic cell systems and methods for treating homocystinuria
CN108795913B (zh) * 2018-05-04 2021-07-02 山西大学 一种植物中能催化h2s产生的酶及其应用
WO2020086937A1 (en) 2018-10-26 2020-04-30 Board Of Regents, The University Of Texas System Engineered primate cystine/cysteine degrading enzymes for therapeutic uses
WO2020264333A1 (en) * 2019-06-26 2020-12-30 Orphan Technologies, Ltd. Pegylated cystathionine beta synthase for enzyme therapy for treatment of homocystinuria
EP4025243A4 (en) * 2019-09-03 2023-09-27 Travere Therapeutics Switzerland GmbH CYSTATHIONINE BETA-SYNTHASE ENZYMA THERAPY FOR THE TREATMENT OF HIGH HOMOCYSTEINE LEVELS
USD1014518S1 (en) * 2021-07-09 2024-02-13 The Regents Of The University Of Colorado, A Body Corporate Display screen or portion thereof with graphical user interface
USD1013704S1 (en) * 2021-07-09 2024-02-06 The Regents Of The University Of Colorado, A Body Corporate Display screen or portion thereof with graphical user interface
CN115721735A (zh) * 2022-10-13 2023-03-03 呈诺再生医学科技(北京)有限公司 Cbs基因在制备糖尿病视网膜病变治疗药物中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57209206A (en) 1981-06-08 1982-12-22 Kanebo Ltd Skin type pack agent
US5523225A (en) 1993-09-13 1996-06-04 Regents Of The University Of Colorado DNA sequence encoding human cystathionine β-synthase
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5730990A (en) 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US5635375A (en) 1995-01-09 1997-06-03 Regents Of The University Of Colorado Method of increasing the yield and heme saturation of cystathione β-synthase
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
US6635438B2 (en) * 1999-11-02 2003-10-21 Catch, Inc. Enzymatic cycling assays for homocysteine and cystathionine
US7485307B2 (en) 2002-06-17 2009-02-03 The Regents Of The University Of Colorado Human cystathionine β-synthase variants and methods of production thereof
EP1396537A1 (en) 2002-09-04 2004-03-10 Avidis SA Treatment of elevated plasma homocysteine
CN101322840A (zh) * 2008-05-28 2008-12-17 中国人民解放军军事医学科学院卫生学环境医学研究所 一种人胱硫醚β-合成酶重组蛋白及应用
MX2013000319A (es) 2010-07-01 2013-05-01 Isis Innovation Tratamiento de transtornos cognitivos.
US9034318B2 (en) 2011-08-30 2015-05-19 The Regents Of The University Of Colorado, A Body Corporate Chemically modified cystathionine beta-synthase enzyme for treatment of homocystinuria
US9243239B2 (en) 2012-03-26 2016-01-26 The Regents Of The University Of Colorado, A Body Corporate Purification of cystathionine beta-synthase
US9675678B2 (en) * 2013-01-29 2017-06-13 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for treatment of homocystinuria

Also Published As

Publication number Publication date
CN112574982B (zh) 2025-05-13
US10046036B2 (en) 2018-08-14
JP2016506727A (ja) 2016-03-07
AU2014212471B2 (en) 2019-11-28
AU2014212471A1 (en) 2015-07-23
EP4406536A3 (en) 2025-01-01
US20150344864A1 (en) 2015-12-03
HK1249137A1 (en) 2018-10-26
US20180311325A1 (en) 2018-11-01
US9034318B2 (en) 2015-05-19
DK3712264T3 (da) 2024-05-06
EP4406536A2 (en) 2024-07-31
JP2019059768A (ja) 2019-04-18
AU2020200719A1 (en) 2020-02-20
WO2014120770A1 (en) 2014-08-07
JP6453243B2 (ja) 2019-01-16
PT3712264T (pt) 2024-05-09
IL239783A0 (en) 2015-08-31
CN112574982A (zh) 2021-03-30
CN105452457A (zh) 2016-03-30
EP2951299A1 (en) 2015-12-09
EP3282013A1 (en) 2018-02-14
AU2022263598A1 (en) 2022-12-15
CA2898772A1 (en) 2014-08-07
AU2020200719B2 (en) 2022-08-18
BR112015017775A2 (pt) 2017-11-21
AU2022263598B2 (en) 2025-06-05
EP2951299B1 (en) 2017-07-12
US20140212403A1 (en) 2014-07-31
EP3712264A1 (en) 2020-09-23
US20170065687A1 (en) 2017-03-09
EP3712264B1 (en) 2024-04-10
IL239783B (en) 2019-10-31
HK1213291A1 (zh) 2016-06-30
US9447406B2 (en) 2016-09-20
JP7580822B2 (ja) 2024-11-12
JP2021000142A (ja) 2021-01-07
US10624959B2 (en) 2020-04-21
JP7240743B2 (ja) 2023-03-16
JP2023062201A (ja) 2023-05-02
EP3712264A8 (en) 2020-11-04
EP3282013B1 (en) 2020-05-20
AU2014212471A8 (en) 2015-08-13
DK3712264T5 (da) 2024-08-26

Similar Documents

Publication Publication Date Title
FI3712264T3 (fi) Kystationiini-beta-syntaasientsyymi homokystinurian hoitoon
JP2016506727A5 (cg-RX-API-DMAC7.html)
CA2846598C (en) Treatment of degenerative joint disease
EP4299118A3 (en) Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
EA201200515A1 (ru) Полипептиды и их применение
EA201290395A1 (ru) Иммуномодулирующие полипептиды, полученные из il-2, и их применение для лечения рака и хронических инфекций
RU2018122823A (ru) Мутанты белка f rsv
MY171146A (en) Compositions of glp-1 peptides and preparation thereof
EA201491513A1 (ru) Рекомбинантные штаммы escherichia coli
EA201990885A1 (ru) Композиции, содержащие короткие пептиды, полученные из pedf, и их применение
WO2012012600A3 (en) Peptide compounds for regulating the complement system
RU2017114673A (ru) Слитый белок, наночастица, состоящая из множества мономеров указанного слитого белка, и их применение
JP2014529399A5 (cg-RX-API-DMAC7.html)
RU2015110114A (ru) Ангиотензин в лечении состояний головного мозга
AR071574A1 (es) Uso de variantes de igf -i pegiladas para el tratamiento de trastornos neuromusculares
WO2013096868A3 (en) Saposin-a derived peptides and uses thereof
RU2016152151A (ru) Препарат, содержащий фактор viii и пептиды фактора фон виллебранда
JP2012102105A5 (cg-RX-API-DMAC7.html)
JP2020520677A5 (cg-RX-API-DMAC7.html)
EA201590601A1 (ru) Применение pedf-производных полипептидов для лечения остеоартрита
AR095076A1 (es) Péptidos y composiciones para el tratamiento de daño articular
JP2011528334A5 (cg-RX-API-DMAC7.html)
WO2019197563A3 (en) Immunogenic compounds for treatment of fibrosis, autoimmune diseases and inflammation
JP2013542196A5 (cg-RX-API-DMAC7.html)
MX2013003545A (es) Peptidos del veneno de escorpion rhopalorus junceus y composicion farmaceutica.